Ronald M. Bukowski

Cleveland Clinic — United States

Medicine · Health Sciences

90h-index44.9kcitations616works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Renal cell carcinoma treatment(282), Cancer Genomics and Diagnostics(130), Renal and related cancers(125), Cancer Immunotherapy and Biomarkers(77), Immunotherapy and Immune Responses(59)

Publications615 total

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma
Journal of Clinical Oncology·2023· 164 cited
Supplementary Tables S1-S2 from Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
2023Open Access
Supplementary Tables 1-7 from Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
2023Open Access
Supplementary Tables S1-S2 from Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
2023Open Access
Supplementary Tables 1-7 from Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
2023Open Access
Data from Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
2023Open Access
Data from Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
2023Open Access
Supplementary Figure 1 from Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
2023Open Access
Supplementary Figure 1 from Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
2023Open Access
Data from Sunitinib Mediates Reversal of Myeloid-Derived Suppressor Cell Accumulation in Renal Cell Carcinoma Patients
2023Open Access
Supplementary Figure 2 from Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
2023Open Access
Data from Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
2023Open Access
Supplementary Figure 2 from Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group
2023Open Access
Supplementary Figure 1 from GM1 and Tumor Necrosis Factor-α, Overexpressed in Renal Cell Carcinoma, Synergize to Induce T-Cell Apoptosis
2023Open Access
Supplementary Figure 1 from GM1 and Tumor Necrosis Factor-α, Overexpressed in Renal Cell Carcinoma, Synergize to Induce T-Cell Apoptosis
2023Open Access
Data from GM1 and Tumor Necrosis Factor-α, Overexpressed in Renal Cell Carcinoma, Synergize to Induce T-Cell Apoptosis
2023Open Access
Data from GM1 and Tumor Necrosis Factor-α, Overexpressed in Renal Cell Carcinoma, Synergize to Induce T-Cell Apoptosis
2023Open Access
Commentary: Meta-Analyses Reporting the Prognostic Value of Androgen Receptor Splice Variant 7 in Castration-Resistant Prostate Cancer
Frontiers in Oncology·2020Open Access
Summary from the Kidney Cancer Association’s Inaugural Think Thank: Coalition for a Cure
Clinical Genitourinary Cancer·2020· 10 cited
Meet Our Editorial Board Member
Current Cancer Therapy Reviews·2018
page 1 of 31Next →

Frequent Co-authors

Brian I. Rini(13), Robert J. Motzer(12), Robert A. Figlin(11), M. Dror Michaelson(10), Thomas E. Hutson(9), Cezary Szczylik(9), Paul Elson(9), Stéphane Oudard(8), Sylvie Négrier(8), Bernard Escudier(8), Laura S. Wood(7), Sindy T. Kim(6), George Wilding(6), Toni K. Choueiri(6), James H. Finke(6), Walter M. Stadler(5), Ali Golshayan(5), Piotr Tomczak(4), Isan Chen(4), Tim Eisen(4)